Replimune Group (Replimune Group) ROC % : -316.70% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Replimune Group's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was -316.70%.

As of today (2024-06-07), Replimune Group's WACC % is 6.43%. Replimune Group's ROC % is -331.29% (calculated using TTM income statement data). Replimune Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Replimune Group ROC % Historical Data

The historical data trend for Replimune Group's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group ROC % Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROC %

Get a 7-Day Free Trial

-131.71

-116.21

-170.57

-252.14

-319.98

Replimune Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROC %	Get a 7-Day Free Trial															-305.26	-325.18	-374.66	-322.68	-316.70

Replimune Group ROC % Calculation

Replimune Group's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2024 is calculated as:

	ROC % (A: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Mar. 2023 )	+	Invested Capital (A: Mar. 2024 ))	/ count )
=	-232.853 * ( 1 - -0.19% )	/	( (70.648	+	75.17)	/ 2 )
=	-233.2954207	/	72.909
=	-319.98 %

where

	Invested Capital		(A: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	646.591	-	17.165	-	( 583.386	-	max(0, 33.825	-	592.603	+	583.386	))
=	70.648

	Invested Capital		(A: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	487.722	-	19.323	-	( 420.668	-	max(0, 40.438	-	433.667	+	420.668	))
=	75.17

Replimune Group's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-232.348 * ( 1 - 0.12% )	/	( (71.383	+	75.17)	/ 2 )
=	-232.0691824	/	73.2765
=	-316.70 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	532.93	-	21.033	-	( 466.351	-	max(0, 38.65	-	479.164	+	466.351	))
=	71.383

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	487.722	-	19.323	-	( 420.668	-	max(0, 40.438	-	433.667	+	420.668	))
=	75.17

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

Replimune Group (NAS:REPL) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Replimune Group's WACC % is 6.43%. Replimune Group's ROC % is -331.29% (calculated using TTM income statement data). Replimune Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Replimune Group ROC % Related Terms

Thank you for viewing the detailed overview of Replimune Group's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group (Replimune Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

7R8:Germany

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Executives

Christopher Sarchi	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos	officer: Chief Medical Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pamela Esposito	officer: Chief Business Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Sushil Patel	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Andrew Schwendenman	officer: Chief Accounting Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Philip Astley-sparke	director, 10 percent owner, officer: Executive Chairman	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Robert Coffin	director, 10 percent owner, officer: President and C.E.O.	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin	10 percent owner, officer: Chief Operating Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Jean M. Franchi	officer: Chief Financial Officer	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139